• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Pangea Biomed’s ENLIGHT-DP Predicts Cancer Treatment Response from Simple Scans

by Fred Pennic 07/03/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Pangea Biomed, a leader in precision oncology, announced a significant breakthrough in its ENLIGHT cancer response predictor. A new study published in Nature Cancer demonstrates the effectiveness of their ENLIGHT-DP platform, revealing its ability to predict cancer treatment response across various types and drugs using only routine pathology slides.

– While these findings are promising, further validation and testing are planned for regulatory approval.

Challenges in Personalized Cancer Treatment

Current methods for predicting cancer treatment response from tissue samples often require large datasets of matched images and treatment outcomes for each specific drug. This data scarcity limits their applicability and generalizability.

ENLIGHT-DP: A Versatile Solution

The ENLIGHT-DP method tackles these limitations with a two-step approach:

  1. DeepPT: This deep learning technology predicts gene expression from standard H&E stained pathology slides.
  2. ENLIGHT: This utilizes the inferred gene expression data to predict patient response to specific treatments.

Key Advantages of ENLIGHT-DP

  • Bypasses Data Limitations: ENLIGHT-DP eliminates the need for extensive, drug-specific training data, making it broadly applicable.
  • Improved Accuracy: Studies show the odds of a successful treatment response more than doubled using ENLIGHT-DP recommendations (odds ratio: 2.28).
  • Wider Applicability: The method works across various cancers and treatment options, potentially transforming clinical practices.

“ENLIGHT-DP bypasses the data availability limitations that hinder existing approaches by eliminating the need for dedicated training on new cohorts for each drug treatment,” said Ranit Aharonov, Pangea’s CTO, who co-led the study. “This versatile solution can be applied across various cancer types and therapies, potentially transforming clinical practices and significantly improving patient outcomes.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Cancer Diagnostics, Oncology Platform

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |